Karyopharm Therapeutics Inc. Stock
Karyopharm Therapeutics Inc. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
With a target price of 18 € there is potential for a 3225.94% increase which would mean more than doubling the current price of 0.54 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 0.490% | 0.690% | -13.021% | -56.987% | -8.259% | -53.119% | -93.017% |
| Evolus Inc | -2.210% | -2.747% | -14.078% | -72.977% | -35.046% | -57.091% | -66.477% |
| Sangamo Therapeutics Inc. | -2.330% | 10.544% | -23.168% | -62.173% | 5.803% | -86.723% | -96.148% |
Comments
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat